Tenet Healthcare has regained complete ownership of its revenue cycle management subsidiary Conifer, buying out CommonSpirit Health's minority stake in a deal valued at nearly $2.7 billion. The move signals Tenet's renewed commitment to the business and plans for significant AI investment.
Despite OPEC+ maintaining production cuts, crude benchmarks fell sharply on Monday, pulling energy stocks like ConocoPhillips down with them as immediate fears of a supply disruption in the Persian Gulf subsided.
The Walt Disney Company's latest quarterly results surpassed Wall Street's modest expectations, yet its stock failed to rally. While its Experiences division continues to be a profit powerhouse and streaming turns a corner, broader challenges and a shrinking 'beat' margin leave investors watching for a catalyst.
A Barcelona hospital has completed a groundbreaking facial transplant, the first of its kind globally where the donor offered her face as part of an assisted dying process. The recipient, who lost facial function to a severe infection, is now recovering well.
Amidst market volatility, Microsoft's diversified empire—spanning cloud, AI, productivity, and gaming—positions it as a resilient long-term holding for investors looking beyond short-term fluctuations.
In a bold marketing move, telehealth company Hims & Hers is leveraging the Super Bowl's massive audience to spotlight healthcare inequality with its 'Rich People Live Longer' campaign. The push comes as the company expands into advanced diagnostics and treatments, while its stock navigates a significant valuation gap after recent volatility.
While Las Vegas Sands shares have struggled to keep pace with the broader market, a majority of Wall Street analysts maintain a constructive outlook, betting on a recovery in Macau and the company's long-term integrated resort model.
As sports betting handles hit record highs, data reveals a stark contrast: the average bettor consistently loses, while disciplined investing in instruments like index funds builds wealth over time.
Shareholders in Harley-Davidson's electric motorcycle spinoff, LiveWire Group, have seen their holdings erode dramatically over five years, with a recent $55 million weekly loss adding to the pain. The company's ongoing revenue contraction raises fundamental questions about its path to profitability in the competitive EV market.
A new report from crypto market maker Wintermute Ventures forecasts a seismic shift, arguing that blockchain-based prediction markets will begin displacing traditional insurance by making hyper-specific risks tradable. The firm outlines a future where decentralized infrastructure becomes the new clearing layer for a programmable global economy.
A sharp reversal in gold and silver prices, coupled with a slide in Bitcoin and Asian equities, rattled investors at the start of February, raising questions about the sustainability of recent market rallies.
As United Parcel Service executes a strategic overhaul focused on profitability over volume, its financials reveal a nascent but promising trend, leading some investors to see a potential rebound on the horizon despite recent stock declines.
Despite a post-earnings sell-off, Netflix's burgeoning advertising business is laying the groundwork for sustained profit growth, presenting a potential value entry for long-term investors.
Lake Street Capital maintains a Buy rating on The ONE Group Hospitality (STKS) despite lowering its price target, citing a solid finish in a tough market and a clear growth runway through 2026.
FreightTech innovator GenLogs has closed a $60 million Series B round led by Battery Ventures. The startup, founded by a former CIA officer, leverages a vast sensor network and AI to bring unprecedented visibility and security to the fragmented trucking industry.
Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
Garrett Motion (GTX) is drawing strong buy ratings from analysts, with a median price target suggesting over 20% upside, driven by its strategic pivot to zero-emission vehicle technologies and resilient financial profile.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
